OGN

NEUTRALM&A

Organon & Co.

2026-06-23

Price

$13.45

+0.37%

This is the 2026-06-23 snapshot — the signals and analysis for OGN as of this single trading day.

View full OGN research hub →

Score11.9Top Tier

Signals6/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 7

Volume0.5xvs 20d avg

Analysis

OGN's exceptionally low 3.5% volatility and steady price action are textbook signatures of a merger arbitrage spread, anchored by Sun Pharma's pending $14.00/share all-cash acquisition. The pristine macro backdrop, highlighted by ultra-tight 0.74% credit spreads, provides massive institutional confidence that the M&A transaction will close without financing friction. Recent fundamental wins—including the MIUDELLA IUD licensing and Canadian biosimilar launches—further de-risk the company's standalone value, perfectly explaining the 'QUIET_STORM' and 'ALPHA_MALE' accumulation signals as arb funds confidently absorb shares.

Fired Signals

SURGEALPHA MALEQUIET STORMGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSELLER FATIGUESMA BOUNCE

Key Takeaways

M&A Arbitrage Anchor: Price action is tightly tethered to the pending $14.00 all-cash buyout from Sun Pharma, explaining the compressed 3.5% realized volatility.
Standalone De-risking: Recent milestones, including the MIUDELLA IUD licensing and Canadian biosimilar launches, bolster the fundamental floor if the deal faces hurdles.
Supportive Macro: A RISK_ON regime with pristine credit spreads ensures robust liquidity, virtually eliminating M&A financing risks for the acquirer.

← Back to 2026-06-23 View Full OGN History →Yahoo Finance &nearr;